Novozymes A/S

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis'. Novonesis means ‘A new beginning' and derives from the Greek word ‘genesis'. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

December 12, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_Conditional competition clearance from the European Commission obtained

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained

Danish food ingredients and enzymes makers Novozymes and Chr. Hansen are expected to secure EU antitrust approval for their all-share $22 billion tie-up based on remedies offered to address competition concerns, two people with direct knowledge of the matter said on Wednesday.

Exclusive: Novozymes, Chr. Hansen tie-up likely to win EU nod, sources say

November 20, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_Update on the merger approval process for the combination of Novozymes and Chr.

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

Novozymes has launched a new enzymatic solution that enables efficient processing of mixed feedstocks for renewable diesel and sustainable aviation fuel production.  The Danish company's Quara LowP product is designed to transform the feedstock pre-treatment process, allowing flexibility to process blends of vegetable oils with other lipid feedstocks without negatively impacting customers' bottom line.

Novozymes innovation enables blending of multiple renewable fuels

Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution designed to transform the feedstock pre-treatment process.

Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

Novozymes A/S (OTCPK:NVZMF) Q3 2023 Results Conference Call October 26, 2023 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Lars Green - Chief Financial Officer Tina Fanoe - EVP, Agriculture & Industrial Biosolutions Amy Byrick - EVP, Strategy and Business Transformation Anders Lund - EVP, Consumer Biosolutions Claus Fuglsang - CSO and EVP of Research and Development. Conference Call Participants Gunther Zechmann - Bernstein Søren Samsøe - SEB Lars Topholm - Carnegie Chetan Udeshi - JPMorgan André Thormann - Danske Bank Ranulf Orr - Citi Charles Bentley - Jefferies Alex Sloane - Barclays Operator Welcome to the Novozymes conference call regarding the interim report for the first 9 months of 2023.

Novozymes A/S (NVZMF) Q3 2023 Earnings Call Transcript

After the first nine months of the 2023 financial year, Novozymes sees increasing demand for sustainable biosolutions and delivers 5 % organic sales growth. The full-year organic sales growth outlook is maintained at 4-6%.

Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations

Element Solutions Inc

Investors with an interest in Chemical - Specialty stocks have likely encountered both Element Solutions (ESI) and Novozymes A/S (NVZMY). But which of these two companies is the best option for those looking for undervalued stocks?

ESI or NVZMY: Which Is the Better Value Stock Right Now?

Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moat around its business, making the company a good long-term investment.

Novozymes: Close To Being A Buy Again

October 10, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_Novozymes announce the Executive Leadership Team and organizational structure

Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen

Read the full announcement in PDF Attachment 2023_57_Executive_Leadership_Team

Executive Leadership Team and organizational structure announced for the future combined company of Novozymes and Chr. Hansen

Ambev

Adyen NV

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Diageo

FANUC Corp

GlaxoSmithKline

Imperial Brands PLC

JD.com

Medtronic

Omron Corp

Roche Holding AG

Safran SA

Shimano Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The October 2023 Heat Map

World's Leading Biotech Powerhouse Recognized for Providing and Advocating for Ingredients that Create Safer Detergents FRANKLINTON, N.C. , Oct. 3, 2023 /PRNewswire/ -- Novozymes was named a 2023 Safer Choice® Partner of the Year by the U.S. Environmental Protection Agency (EPA) for outstanding achievement in the manufacture of ingredients that are safer for families, pets, workplaces, communities, and the environment.

Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row

Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes' commitment to driving innovation in biosolutions and promoting sustainable food choices.

Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives

PPG Industries

Investors with an interest in Chemical - Specialty stocks have likely encountered both PPG Industries (PPG) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?

PPG or NVZMY: Which Is the Better Value Stock Right Now?

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.

Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption.

Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs

Investors with an interest in Chemical - Specialty stocks have likely encountered both PPG Industries (PPG) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

PPG vs. NVZMY: Which Stock Is the Better Value Option?

Novozymes A/S (OTCPK:NVZMF) 1H 2023 Earnings Conference Call August 9, 2023 3:00 AM ET Company Participants Tobias Bjorklund - Head of investor relations Ester Baiget - President and CEO Lars Green - EVP and CFO Amy Byrick - EVP, Strategy and Business Transformation Tina Fano - EVP, Agriculture and Industrial Biosolutions Anders Lund - EVP, Consumer Biosolutions Claus Fuglsang - CSO and EVP of Research and Development Conference Call Participants Alexander Jones - Bank of America Lars Topholm - Carnegie Investment Chetan Udeshi - J.P. Morgan Soren Samsoe - SEB Nicola Tang - Exane BNP Paribas Sebastian Bray - Berenberg Operator Welcome to the Novozymes conference call regarding the Interim Report for the First Half Year of 2023.

Novozymes A/S (NVZMF) 1H 2023 Earnings Call Transcript

After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3 % organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing.

Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook

Assa Abloy AB

Sanofi

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth it.

International Wide-Moat Stocks On Sale - The August 2023 Heat Map

Baidu

Reckitt Benckiser Group PLC

Tencent Holdings Limited

International Wide-Moat Stocks On Sale - The July 2023 Heat Map

New Linde PLC

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Linde (LIN) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

LIN vs. NVZMY: Which Stock Is the Better Value Option?

Allegion

Experian PLC

Toronto-Dominion Bank

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The May 2023 Heat Map

News for Novozymes A/S Stock (NVZMY)